Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company’s compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company’s compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
Market Cap:208.7M; Shares Outstanding:45.4M; Short Interest: 1.01%; Q3 2019(9/30/19): Cash 114M Loss 14.79M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 67，Reduced 1
Shares hold: 17485.6k shares.no change
shares% hold: 39.88%，no change